Sophie Paczesny | Immunotherapy | Best Researcher Award

Published on by Cell Biologist

Prof. Sophie Paczesny | Immunotherapy | Best Researcher Award

Prof. Sophie Paczesny, Medical Univeristy of South Carolina, United States

Dr. Sophie Paczesny, M.D., Ph.D., is an internationally recognized leader in immunology and cancer research. Currently, she serves as Professor of Immunology & Pediatrics and the Sally Abney Rose Endowed Chair in Cancer Stem Cell Biology at the Medical University of South Carolina (MUSC). She is also Co-Leader of the Cancer Biology & Immunology Program at the Hollings Cancer Center. With a deep commitment to improving outcomes in hematopoietic cell transplantation, her translational research bridges clinical and laboratory advances in graft-versus-host disease (GVHD), biomarkers, and tumor immunology. Her work has shaped diagnostic and therapeutic strategies across pediatric and adult oncology. Dr. Paczesny’s pioneering studies on dendritic cell vaccines and immune reconstitution have led to impactful, high-citation publications in journals like Blood, JCI Insight, and Journal of Clinical Oncology. She continues to mentor the next generation of physician-scientists while advancing cutting-edge immune-oncology research globally.

Publication Profile: 

Orcid

Scopus

✅ Strengths for the Award:

  1. Pioneering Work in Immunology & Transplantation
    Dr. Paczesny has significantly advanced our understanding of graft-versus-host disease (GVHD) through the development of novel biomarkers, improving diagnostics, patient stratification, and therapeutic decisions in hematopoietic cell transplantation.

  2. High-Impact Publications
    With over 20 influential publications, including in Blood, JCI Insight, Journal of Clinical Oncology, and British Journal of Haematology, she has made consistent contributions to high-impact journals, underscoring the translational value of her work.

  3. Strong Interdisciplinary Background
    Her dual degrees (M.D., Ph.D.), combined with training across mathematics, life sciences, tumor immunology, and cell therapy, enable her to bridge basic science and clinical application effectively.

  4. Leadership and Mentorship
    Holding senior positions such as Professor, Endowed Chair, and Program Co-Leader at MUSC, she demonstrates strong leadership and commitment to fostering academic growth in immunology and pediatrics.

  5. Global and Collaborative Impact
    Her participation in international collaborations and consortia (e.g., Pediatric Transplant and Cellular Therapy Consortium) highlights her global influence and scientific diplomacy.

  6. Innovative Clinical Translation
    She led or contributed to the development of decision-support tools (e.g., biomarker-based decision trees for VOD/SOS), which have the potential to shift real-world clinical practices.

⚙️ Areas for Improvement:

  1. Outreach & Visibility
    Despite her extensive contributions, Dr. Paczesny may benefit from more frequent keynote talks, scientific media presence, or public engagement efforts to raise broader awareness of her work among policymakers, patients, and industry.

  2. Startup/Commercial Translation
    While highly research-driven, expanding into biotech or diagnostic tool commercialization could further translate her biomarker discoveries into scalable clinical solutions.

  3. Grant Leadership Details
    The provided information doesn’t detail the scope of grants led (e.g., NIH R01s, consortia P01s). Adding these details could strengthen evaluations by funding and award committees.

🎓 Education:

Dr. Paczesny began her academic journey in France, earning a B.S. in Mathematics and Life Sciences from the Academy of Nancy-Metz (1985–1989). She pursued her M.D. at the University of Strasbourg, completing her medical degree in 1995. Her passion for cellular therapies led her to obtain an M.S. in Cell Therapy and Biology of Hematopoietic Cells from the University of Paris VII in 1999. She continued her scientific training by earning a Ph.D. in Tumor Immunology at the same institution in 2004. Her educational background reflects a unique blend of clinical training and basic science, providing the foundation for her translational research in immunology and cancer biology. This multidisciplinary training has enabled her to tackle complex clinical problems like graft-versus-host disease and immune response modulation from both therapeutic and mechanistic angles.

🩺 Professional Experience:

Dr. Sophie Paczesny has held academic and clinical positions in both Europe and the United States. She began her faculty career as Assistant Professor of Pediatrics at the University and Hospitals of Nancy (2003–2005). She transitioned to the U.S. as Assistant Professor of Pediatrics and Communicable Diseases at the University of Michigan (2009–2012). From 2012–2015, she served as Associate Professor at Indiana University School of Medicine, holding appointments in Pediatrics, Microbiology, and Immunology. She also contributed to the Melvin and Bren Simon Cancer Center. Currently, she is a Professor at the Medical University of South Carolina (MUSC), where she leads research and training efforts in immunology and cancer biology. Across all roles, she has led NIH-funded programs, advanced biomarker research, mentored junior investigators, and contributed to the development of immunotherapeutic approaches in hematopoietic cell transplantation and cancer.

🏅 Honors and Awards:

Dr. Paczesny has received numerous honors recognizing her contributions to science and medicine. In 1999, she earned Second Prize at the Avicenne Hospital Research Meeting in Paris. In 2000, she was awarded the Médaille d’Argent (Silver Medal) from Paris University Hospitals’ residency program. That same year, she co-received First Prize for Best Fellow Academic Work in France, acknowledging her early excellence in clinical and research training. Her ongoing research has been consistently supported by competitive grants and featured in high-impact journals, highlighting her leadership in biomarker discovery and immune-oncology. As an endowed chair at MUSC and an invited speaker at leading international conferences, her work continues to gain recognition. These awards underscore both her clinical insight and scientific innovation, particularly in the fields of transplant immunology and cancer immunotherapy.

🔬 Research Focus:

Dr. Paczesny’s research is centered on translational immunology, with a special focus on graft-versus-host disease (GVHD), immune reconstitution, and cancer immunotherapy. She has pioneered the use of biomarkers to predict outcomes and complications in hematopoietic stem cell transplantation, including veno-occlusive disease and chronic GVHD. Her studies have uncovered novel immune pathways and prognostic indicators, many of which have informed clinical trials and therapeutic strategies. Additionally, she explores dendritic cell vaccines, immunopeptidomics, and HLA allele influences on transplant success. Her collaborative projects span pediatric and adult immunology, contributing to national consortia such as the Pediatric Transplant and Cellular Therapy Consortium. Her ultimate goal is to enhance survival while reducing toxicities of transplantation through immune-guided, precision medicine approaches. She is especially known for integrating advanced statistical modeling and immunobiology to address real-world clinical challenges.

📚 Publications Top Notes: 

  1. 🧫 Protection of mice against leukemia after vaccination with dendritic cells – Cancer Research (2001)

  2. 💉 Monoclonal anti-IL-6 antibody treatment in B-lymphoproliferative disorder – Blood (2001)

  3. 🧬 CD34+ dendritic cell vaccine induces T-cell immunity in melanoma – J Immunother (2003)

  4. 🦠 Dendritic cells as immune controllers and therapeutic tools – Ann NY Acad Sci (2003)

  5. 🎯 Dendritic cells as vectors for cancer immunotherapy – Semin Cancer Biol (2003)

  6. 🧪 Melanoma vaccines using dendritic cells – Dev Biol Basel (2004)

  7. 🧫 CD8+ T-cell expansion in melanoma patients post-vaccination – J Exp Med (2004)

  8. 🧾 Tumor inhibition assay for CTL response post-vaccine – J Immunother (2005)

  9. 🔁 Peptide-pulsed dendritic cells boost melanoma-specific CD8+ T cells – J Immunother (2005)

  10. 📈 Advances in dendritic cell-based immunotherapy – Adv Exp Med Biol (2005)

🧾 Conclusion:

Dr. Sophie Paczesny embodies the ideal recipient of the Best Researcher Award. She has made transformative contributions to immunology, stem cell biology, and cancer therapeutics, particularly in the field of biomarker-driven precision medicine. Her leadership in both academia and collaborative clinical research has shaped safer and more effective treatment strategies for transplant patients worldwide.

Her depth of expertise, sustained research output, and ongoing innovations place her at the forefront of translational immunology. While minor gains could be made in public visibility and translational enterprise, her impact on science and patient care is profound.

Wei Mu | Immunotherapy and Molecular Pathology | Best Researcher Award

Published on by Cell Biologist

Dr. Wei Mu | Immunotherapy and Molecular Pathology | Best Researcher Award

Dr. Wei Mu , Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , China

Mu Wei, born in October 1989, is an Assistant Researcher in the Department of Hematology at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. With a solid foundation in biotechnology and regenerative medicine, Mu Wei has consistently contributed to the advancement of CAR-T cell therapy, particularly in the context of hematological diseases. His research blends molecular biology with cutting-edge therapeutic techniques to tackle complex issues like T-cell exhaustion and immunotherapy resistance. With multiple principal investigator roles and ongoing projects funded by the National Natural Science Foundation of China, his expertise is shaping the future of cancer immunotherapy. Mu Wei is also an active author with publications in top-tier scientific journals, contributing valuable insights into CAR-T cell dynamics and the molecular mechanisms underlying immune responses in hematological malignancies.

Publication Profile:

Scopus

Strengths for the Award:

  1. Innovative Research Focus: Mu Wei’s research on CAR-T cell therapy demonstrates significant potential to enhance cancer immunotherapy. His work on precise molecular regulation of IL2Rβ/IL2Rγ signaling and T-cell exhaustion mechanisms in CAR-T therapies is cutting-edge and addresses key challenges in the field of hematological malignancies.
  2. Leadership and Impact: As the principal investigator for several National Natural Science Foundation projects, Mu Wei has shown leadership in guiding important research initiatives aimed at improving CAR-T cell therapies. His work is already showing potential to directly influence clinical outcomes in blood cancers.
  3. Publication Record: His consistent publication in high-impact journals (e.g., Blood Cancer Journal, Cell Reports) and contributions to collaborative studies further solidify his recognition as a leader in his research area.
  4. Ongoing Funding and Collaboration: The fact that Mu Wei is a key participant in ongoing large-scale national research projects demonstrates his ability to collaborate and contribute to high-impact, multi-year scientific endeavors. These projects reflect both the trust placed in him by funding bodies and the relevance of his expertise.

Areas for Improvement:

  1. Broader International Exposure: While Mu Wei has made impressive strides in national research, expanding his collaborations and visibility in international scientific communities could further boost the global impact of his research.
  2. Broader Public Engagement: As his research has direct implications for patient care, more efforts in translating his work into publicly accessible formats—such as public outreach, media engagement, or policy advisory—could amplify the societal impact of his discoveries.
  3. Expansion into Related Fields: His focus is currently tightly centered on CAR-T therapy in hematology. Branching into additional related areas, such as solid tumor immunotherapy or alternative immunotherapy strategies, could diversify his research portfolio and increase its relevance to a broader range of cancers.

 

Education:

Mu Wei completed his B.S. in Biotechnology at Anhui Medical University in 2011, followed by a Ph.D. in Regenerative Medicine from the University of Chinese Academy of Sciences in 2018. His doctoral research focused on the molecular biology of regenerative therapies, laying the foundation for his current expertise in hematology and immunology. During his Ph.D., Mu Wei developed a strong interest in immunotherapy, particularly in how cell therapies like CAR-T could be used to treat cancer and other blood disorders. Building on his academic achievements, he continued his training as a Postdoctoral Researcher at Tongji Hospital, where he expanded his research to explore the genetic and immune mechanisms involved in T-cell therapies. His robust educational background is complemented by his continuous pursuit of knowledge in cutting-edge immunotherapy technologies and regenerative medicine.

Experience: 

Mu Wei has extensive experience in hematology and cellular therapy, with a career spanning over a decade. Since December 2021, he has served as an Assistant Researcher in the Department of Hematology at Tongji Hospital, where he leads innovative research projects on CAR-T cell therapy and immunotherapy. Prior to this, he was a Postdoctoral Researcher at the same institution from October 2018 to October 2021, focusing on T-cell engineering and cell exhaustion mechanisms in cancer therapies. His academic and professional journey began at Anhui Medical University, where he earned his B.S. in Biotechnology, followed by a Ph.D. in Regenerative Medicine from the University of Chinese Academy of Sciences. Mu Wei’s work integrates laboratory research with clinical applications, aiming to improve the safety and efficacy of cellular therapies in treating hematological malignancies. He is also actively involved in national-level research projects funded by the National Natural Science Foundation of China.

Research Focus:

Mu Wei’s research focuses on advancing CAR-T cell therapy for the treatment of hematological cancers, with a particular emphasis on improving the precision and efficacy of these therapies. His work explores several critical areas: the molecular regulation of IL2Rβ/IL2Rγ signaling in CAR-T cells, the role of T-cell exhaustion in immunotherapy, and novel strategies to overcome resistance in lymphoma CAR-T cell therapies. By investigating the extracellular vesicle-based regulation of CAR-T cells, Mu Wei aims to develop more effective, targeted immunotherapies with fewer side effects. His current projects also delve into the molecular mechanisms of immune cell exhaustion, which can limit the effectiveness of CAR-T cells in certain patients. Mu Wei is passionate about translating his laboratory findings into clinical applications, improving the outcomes of patients with blood cancers through enhanced CAR-T cell designs and immunotherapeutic approaches. His research promises to contribute to the next generation of cancer immunotherapies.

Publication Top Notes:

  1. Correction to: Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control 🧬🛡️ Blood Cancer Journal (2024)
  2. Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control 🧬🛡️ Blood Cancer Journal (2024)
  3. Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies 🚫🧬 Biomedicine and Pharmacotherapy (2024)
  4. Correlation analysis of polyclonal plasma cell proportion in the bone marrow with clinical characteristics of patients with newly diagnosed multiple myeloma 🩸📊 Chinese Journal of Hematology (2024)
  5. Novel heterozygous mutations of TNFRSF13B in EBV-associated T/NK lymphoproliferative diseases 🧬💉 Blood Science (2024)
  6. Functional diversification and dynamics of CAR-T cells in patients with B-ALL 🔬🧑‍🔬 Cell Reports (2023)
  7. Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia ⚕️💡 Cancer Immunology, Immunotherapy (2023)
  8. Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma 📑🩸 Frontiers in Immunology (2023)
  9. CD137 deficiency because of two novel biallelic TNFRSF9 mutations in a patient presenting with severe EBV-associated lymphoproliferative disease 🧬💉 Clinical and Translational Immunology (2023)
  10. Genetic lesions and targeted therapy in Hodgkin lymphoma 🧬💊 Therapeutic Advances in Hematology (2023)

Conclusion:

Mu Wei is highly deserving of the Best Researcher Award. His research is not only advancing CAR-T cell therapy but is addressing key obstacles in the field, such as T-cell exhaustion and immune resistance. His leadership in national research projects and consistent publication in top-tier journals demonstrate his strong research capabilities. With his clear focus on improving cancer immunotherapy, Mu Wei is poised to make lasting contributions to the field, and his work holds the potential to improve clinical outcomes for patients with blood cancers. Expanding his international collaborations and broadening his research scope could further amplify his impact in the global scientific and clinical communities.